BLB-01D1 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData, Phase I drugs for Non-Small Cell Lung Cancer have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how BLB-01D1’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Likelihood of Approval and Phase Transition Success Rate Model - BLB-01D1 in Non-Small Cell Lung Cancer

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

BLB-01D1 overview

BLB-01D1 (BLB-029A1,SIB-029A) is under development for the treatment of HER 2 negative breast cancer, epithelial tumor, advanced or metastatic urologic tumors, metastatic breast cancer, advanced or metastatic gastrointestinal tumors and Triple-Negative Breast Cancer (TNBC), non-small cell lung cancer, head and neck squamous cell carcinoma, recurrent head and neck squamous cell carcinoma nasopharyngeal carcinoma, small cell lung cancer, metastatic ovarian cancer, epithelial ovarian cancer, primary peritoneal cancer, endometrial cancer, vulvar cancer, vaginal cancer and primary sarcoma of the gynecological reproductive system, cervical cancer, fallopian tube cancer, metastatic urothelial carcinoma, prostate cancer, renal cell carcinoma, gastric cancer, metastatic colorectal cancer and penile cancer. The therapeutic candidate is a bispecific EGFRxHER3 antibody-drug conjugate (ADC) with a Topo-1 inhibitor payload and a cleavable linker.
It was also under development for the treatment of lung cancer, colon cancer, head and neck cancer. It is administered through intravenous, intravenous drip route and parenteral.

See Also:

Bristol-Myers Squibb overview

Bristol-Myers Squibb (BMS) is a specialty biopharmaceutical company that is engaged in discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, immunology, cardiovascular, and fibrotic therapeutic projects. The company offers its products across the world to wholesalers, retail pharmacies, medical professionals, hospitals and government entities. BMS provides its products in the US, Europe, and Japan. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in Princeton, New Jersey, the US.

For a complete picture of BLB-01D1’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.